Abstract
Two reports demonstrate how new chemical probes for amyloid-β deposits aids in the detection of Alzheimer disease (AD) in vivo.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Hintersteiner, M. et al. In vivo detection of amyloid-β deposits by near-infrared imaging using an oxazine-derivative probe. Nat. Biotechnol. 23, 577–583 (2005).
Sato, K. et al. Fluoro-substituted and 13C-labeled styrylbenzene derivatives for detecting brain amyloid plaques. Eur. J. Med. Chem. 39, 573–578 (2004).
Higuchi, M. et al. 19F and 1H MRI detection of amyloid-β plaques in vivo. Nat. Neurosci. 8, 527–533 (2005).
Rights and permissions
About this article
Cite this article
Evanko, D. Imaging Alzheimer disease: seeing the unseeable. Nat Methods 2, 481 (2005). https://doi.org/10.1038/nmeth0705-481
Issue date:
DOI: https://doi.org/10.1038/nmeth0705-481
